CD49b/Integrin alpha 2/ITGA2 Drug Discovery Landscape & Assay Solutions
- By admin
- 06 Sep 2026
- Comments
Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology, Autoimmune, and Thrombosis Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD49b/ITGA2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ITGA2 (CD49b) ECD-Fc Recombinant Protein High purity (>95%), Endotoxin <1.0 EU/μg. Sequence Verified. HEK293 expressed for native glycosylation. |
View ITGA2 Products |
| Gene Delivery | ITGA2 Lentivirus Premade Particles Full-length human ITGA2 ORF for stable cell line generation. Ideal for preserving native heterodimeric conformation. |
View ITGA2 Products |
| Benchmark Ab | Anti-ITGA2 Recombinant Antibody (Vatelizumab Biosimilar) Recombinant positive control for binding and functional blockade assays. |
View ITGA2 Products |
| Validator | ITGA2 siRNA Set Target-specific knockdown pool for functional validation in cell-based assays. |
View ITGA2 Products |
| Related Target A | ITGB1 (Integrin beta 1 / CD29) Required heterodimerization partner for functional collagen-receptor complex formation. |
View ITGB1 Products |
| Related Target B | Collagen Type I (COL1A1) Primary physiological ligand of the ITGA2/ITGB1 complex; essential for ligand-competition assays. |
View COL1A1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformation-dependent binding (MIDAS domain integrity) | HEK293 mammalian expression ensures native post-translational modifications and correct folding of the I-domain. |
| Cross-species reactivity screening (Human vs. Cynomolgus/Mouse) | Sequence-verified human, cynomolgus, and mouse ortholog proteins available with >95% purity. |
| Lack of standardized positive controls | Recombinant Vatelizumab biosimilar antibody included as a clinical benchmark control. |
| Off-target/subfamily cross-reactivity (Integrin alpha 1/ITGA1) | Counter-screening panel including recombinant ITGA1 available with strict mass spectrometry quality control. |
Live CD49b/ITGA2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of CD49b (Integrin alpha 2) is gaining traction across oncology, immunology, and hematology. In oncology, CD49b is highly expressed on tumor-initiating cells and contributes to chemoresistance and metastasis in pancreatic, prostate, and breast cancers. Consequently, developers are moving beyond simple blocking monoclonal antibodies (mAbs) toward Antibody-Drug Conjugates (ADCs) and CAR-T/CAR-NK cell therapies. In the autoimmune sector, targeting the collagen-binding I-domain of CD49b offers a pathway to modulate T-cell infiltration and inflammatory responses in diseases like ulcerative colitis and multiple sclerosis. The next wave of R&D is focused on selective conformation-specific inhibitors that block ligand binding without inducing unintended platelet activation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugate (ADC) | Preclinical consortia, Biotech startups | Solid Tumors (Pancreatic, Prostate) | Internalization Assay (Requires high-purity, native glycosylated ECD-Fc) |
| Monoclonal Antibody (Blocking) | Genzyme (Vatelizumab/historical), Academic spin-offs | Autoimmune Diseases, Inflammatory Bowel Disease | Ligand-Competition Assay (Requires active ITGA2/ITGB1 complex and Collagen I) |
| Cell Therapy (CAR-T / CAR-NK) | Translational oncology labs, Cell therapy developers | Metastatic cancers, Chemoresistant tumors | Target Density & Specificity Validation (Requires Lentivirus for stable cell lines) |